Ningbo Menovo Pharmaceutical Co., Ltd., a prominent player in the health care sector, has been making significant strides in the pharmaceutical industry. Located in Ningbo, China, the company specializes in the manufacturing of pharmaceutical products, focusing on pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Its primary market is within China, where it has established a strong presence.
As of August 9, 2026, the company’s stock was trading at a close price of 29.2 CNY on the Shanghai Stock Exchange. This reflects a notable fluctuation over the past year, with the stock reaching a 52-week high of 50.2786 CNY on May 6, 2026, and a 52-week low of 13.55 CNY on December 16, 2025. The company’s market capitalization stands at 9,925,903,360 CNY, underscoring its substantial presence in the pharmaceutical sector.
Ningbo Menovo Pharmaceutical’s financial metrics reveal a price-to-earnings (P/E) ratio of 79.89, indicating investor expectations of future growth and profitability. This high P/E ratio suggests that the market has a positive outlook on the company’s future earnings potential, despite the inherent volatility in the pharmaceutical industry.
The company’s strategic focus on pharmaceutical intermediates and APIs positions it well within the supply chain of the pharmaceutical industry. By catering to the needs of both domestic and potentially international markets, Ningbo Menovo Pharmaceutical aims to leverage its expertise and production capabilities to meet the growing demand for pharmaceutical products.
For those interested in learning more about Ningbo Menovo Pharmaceutical’s operations, offerings, and strategic initiatives, further information is available on its official website at www.menovopharm.com . The company continues to play a vital role in the health care sector, contributing to the development and distribution of essential pharmaceutical products in China and beyond.
